Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.

[1]  D. Berry,et al.  Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. R. Lee,et al.  Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. , 2020, JAMA oncology.

[3]  D. Gorovets,et al.  Financial toxicity associated with treatment of localized prostate cancer , 2019, Nature Reviews Urology.

[4]  D. Spratt,et al.  Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.

[5]  D. Kuban,et al.  Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. , 2019, International journal of radiation oncology, biology, physics.

[6]  L. Collette,et al.  A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses , 2019, JNCI cancer spectrum.

[7]  T. J. Moore,et al.  Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 , 2018, JAMA internal medicine.

[8]  H. Sandler,et al.  Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial , 2018, JAMA oncology.

[9]  P. Kantoff,et al.  Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[11]  Amber Jessup,et al.  Key cost drivers of pharmaceutical clinical trials in the United States , 2016, Clinical trials.

[12]  P. Kantoff,et al.  The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). , 2015, Journal of the National Cancer Institute.

[13]  B. Kramer,et al.  Surrogate endpoint analysis: an exercise in extrapolation. , 2013, Journal of the National Cancer Institute.

[14]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[15]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[16]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[17]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[18]  M. Gail,et al.  The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.